Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke[1][2].
Glenzocimab (0-100000 ng/mL) 抑制 GPVI-Fc 与固定在微量滴定板上的胶原蛋白结合，IC50 为 1.37 μg/mL[2]。
Glenzocimab (1-8 mg/kg; i.v.) 抑制食蟹猴中胶原诱导的血小板聚集[2]。
| Animal Model: | Cynomolgus monkeys[2] |
| Dosage: | 1-8 mg/kg |
| Administration: | I.v. |
| Result: | Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus. |
[1]. Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53(11):3506-3513.
[2]. Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9(6):945-958.